Beyond the clinic: Can digital therapeutics (DTx) help boost mental health in the workforce at scale?

By SharpBrains | October 2, 2023

Hop­ing to Avoid Pear’s Fate, Behav­ioral Health-Focused DTx Com­pa­nies Look to Employ­er Mar­ket (Behav­ioral Health Busi­ness): The dig­i­tal ther­a­peu­tics (DTx) indus­try is at a cross­roads after one of the most promi­nent com­pa­nies in the space, Pear Ther­a­peu­tics, filed for bank­rupt­cy ear­li­er this year. The tur­moil comes after DTx began catch­ing on in the behav­ioral health…

Read More

On the 7 Habits of Highly Stress-Resilient Minds, cognitive screenings, anti-amyloid drugs, and more

By SharpBrains | April 27, 2023

Wel­come to a new edi­tion of Sharp­Brains e‑newsletter, this time cov­er­ing the lat­est devel­op­ments in stress research, med­i­ta­tion, vir­tu­al real­i­ty, anti-amy­loid drugs, cog­ni­tive screen­ings, and more. #1. The 7 Habits of High­ly Stress-Resilient Minds “Any­thing worth doing will have aspects of stress woven through: chal­lenge, dis­com­fort, risk. We can’t change that. But what we can change is…

Read More

Pear Therapeutics loses 97% of its market capitalization since 2021, explores strategic alternatives

By SharpBrains | March 29, 2023

Pear Ther­a­peu­tics explor­ing sale, oth­er ‘strate­gic alter­na­tives’ (Mobi­Health News): Pre­scrip­tion dig­i­tal ther­a­peu­tics com­pa­ny Pear Ther­a­peu­tics is explor­ing “strate­gic alter­na­tives,” includ­ing a pos­si­ble com­pa­ny sale, merg­er or acqui­si­tion. In a press release, the com­pa­ny said it hired a finan­cial advi­sor to look into actions that could “max­i­mize share­hold­er val­ue.” That includes a poten­tial sale, M&A, divestiture…

Read More

Debate: Will digital therapeutics gain the required levels of awareness, adoption, reimbursement and fulfillment to become sustainable?

By SharpBrains | April 21, 2022

Can dig­i­tal ther­a­peu­tics become prof­itable? (MedTech­Dive): In 2020, the Food and Drug Admin­is­tra­tion cleared Akili Inter­ac­tive’s video game to improve atten­tion in kids with ADHD. It was the first time that a video game for treat­ment was cleared by the agency, and is one exam­ple of a dig­i­tal ther­a­peu­tic, a class of soft­­ware-based treat­ments with…

Read More

Update: Why MDMA-assisted psychotherapy may become an FDA-approved treatment for PTSD within 2 years

By SharpBrains | December 30, 2021

Wel­come to a new edi­tion of Sharp­Brains’ e‑newsletter, shar­ing impor­tant brain/ men­tal health news plus a few fun opti­cal illu­sions to tease and appre­ci­ate our unique human minds. #1. Why MDMA-assist­ed psy­chother­a­py may become an FDA-approved treat­ment for PTSD with­in 2 years “We are a phar­ma­cist and physi­cian team who inves­ti­gate the ben­e­fits and harms asso­ci­at­ed with…

Read More

Pear Therapeutics raises $175M and goes public via SPAC deal raising the profile of prescription digital therapeutics

By SharpBrains | December 8, 2021

Dig­i­tal health firm Pear goes pub­lic, rais­ing $175 mil­lion (phar­mafo­rum): Pear will make its debut on the exchange today after com­bin­ing with Thim­ble Point – a spe­cial pur­pose acqui­si­tion com­pa­ny (SPAC) – in a deal that side­stepped the con­ven­tion­al ini­tial pub­lic offer­ing (IPO) route and has pro­pelled its val­u­a­tion to around $1.6 bil­lion … Pear specialises…

Read More